Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
Novo Nordisk: Don't Miss Buying This Dip
30.07.2025 14:02
Novo Nordisk's launch of NovoCare is showing signs of boosting Wegovy's sales, and the E.U.-U.S. trade deal adds stability for the new CEO. Learn more on NVO stock here.
Novo Nordisk Stock Got Battered. Think Twice Before Buying the Dip.
30.07.2025 12:02
Novo Nordisk is in the sick bay. The stock had its worst day since Black Monday and Wall Street is becoming increasingly skeptical that the weight-loss drugmaker can play catch-up in an increasingly competitive market. Analysts were lowering their expectations on the stock after Novo slashed its full-year outlook Tuesday citing the persistent use of copycat versions of GLP-1s—a type of gut hormone that help regulate blood sugar levels and control appetite—in the U.S., which it vowed to fight.
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
30.07.2025 12:01
Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1
MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth
30.07.2025 10:05
MENLO PARK, Calif., July 30, 2025--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide.
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
30.07.2025 09:00
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and future outlook.
IXJ: A Bet On Global Healthcare Recovery
30.07.2025 01:33
IXJ offers global healthcare exposure, capturing demographic shifts and innovation trends beyond U.S.-centric ETFs. Read why IXJ ETF is a Buy.
Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again
29.07.2025 11:07
COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this year, sending its shares down as much as 17%. The maker of weight-loss drug Wegovy is struggling to convince investors it can remain competitive in the obesity drug boom against U.S. rival Eli Lilly. "The lowered sales outlook for 2025 is driven by lower growth expectations for the second half of 2025," the company said in a statement.
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
29.07.2025 10:45
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This study enrolled patients with treatment-naïve CLL/SLL and those who had been previously treated but were BTK inhibitor-naïve. The stu
Eli Lilly (LLY) Stock Set to Gain on Early Alzheimer’s Trial Results, Says BMO Capital
29.07.2025 05:37
Eli Lilly & Company (NYSE:LLY) ranks among the stocks to benefit from an onshoring boom. On July 22, BMO Capital reaffirmed its $900 price target and Outperform rating for Eli Lilly & Company (NYSE:LLY). According to the investment firm, an interim analysis of Eli Lilly’s TRAILBLAZER-ALZ 3 presymptomatic Alzheimer’s trial may be done before the […]
Eli Lilly and Company (LLY) Announces New Phase 3 Trial Results for Orforglipron
29.07.2025 05:29
Eli Lilly and Company (NYSE:LLY) is one of the Stocks With Huge Catalysts on the Horizon. On July 21, Eli Lilly and Company (NYSE:LLY) announced new Phase 3 trial results for Orforglipron, which is an oral drug for adults with type 2 diabetes. This comes as a breakthrough for the company as Orforglipron is the first […]
Jim Cramer on Pfizer: “We are Still on the Verge of Finding Out What the Seagen Acquisition Does”
29.07.2025 05:28
Pfizer Inc. (NYSE:PFE) is one of the stocks that Jim Cramer weighed in on. A caller asked if they should continue to hold the stock or sell it. In response, Cramer stated: “I can’t ask you to do that because we are still on the verge of finding out what the Seagen acquisition does. Let’s […]
BME: The Resilient Income Investment Of The Healthcare Industry
29.07.2025 00:02
BlackRock Health Sciences Trust offers a resilient 8.63% dividend yield, low expense ratio, and conservative, low-risk positioning. See more on BME ETF here.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
25.07.2025 13:00
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
25.07.2025 12:49
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
In reversal, European regulators take positive view on Lilly Alzheimer’s drug
25.07.2025 10:42
Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug, Kisunla, one step closer to European market entry.
Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease
25.07.2025 10:27
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending donanemab for the treatment of early symptomatic Alzheimer's disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers. The European Commission is expected to make a regulatory decision on donanemab in the coming months.
Viking Therapeutics Q2: Confidently Continuing The Recovery
25.07.2025 10:15
Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX stock now.
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
23.07.2025 13:15
Shares of Abivax hit the stratosphere Wednesday after the firm unveiled "potentially disruptive" results for its ulcerative colitis drug.
Earnings Preview: What to Expect From Eli Lilly's Report
23.07.2025 11:46
Eli Lilly is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit growth.
Roche’s Elecsys pTau181 test gains CE Mark to rule out Alzheimer’s
23.07.2025 11:26
A multi-centre, prospective trial involving 787 subjects across Australia, Europe, and the US formed the basis for the CE Mark.